buyWeak
Robert James Wills bought $59k of ONCT
director at Oncternal Therapeutics, Inc.. 6,914 shares at an average of $8.48, traded Mar 28, 2024, filed Apr 1, 2024.
Conviction score
30Value
$59k
6,914 shares
Holdings after
6,914
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +7Trade size$59k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-24-005154, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 28, 2024 | POpen-market purchase Common Stock | +6,914 | $8.48 | $59k | 6,914 | Apr 1, 2024 |
Related signals
Other insiders at Oncternal Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | ONCTbuy Oncternal Therapeutics, Inc. | Robert James Wills director | $28k 3,086 shares | +45% | |
| 23Weak | ONCTbuy Oncternal Therapeutics, Inc. | David F Hale director | $8,859 980 shares | - | |
| 35Weak | ONCTsell Oncternal Therapeutics, Inc. | Robert James Wills director | $8,859 980 shares | -100% | |
| 21Weak | ONCTbuy Oncternal Therapeutics, Inc. | Gunnar F. Kaufmann Chief Scientific Officer | $9,824 28,000 shares | +42% | |
| 56Moderate | Oncternal Therapeutics, Inc. | James B Breitmeyer Chief Executive Officer | $44k 150,000 shares | +322% | |
| 36Weak | Oncternal Therapeutics, Inc. | Chase C. Leavitt General Counsel/Secretary | $7,250 25,000 shares | +31% | |
| 43Moderate | Oncternal Therapeutics, Inc. | Richard G Vincent Chief Financial Officer | $8,961 30,000 shares | +24% | |
| 33Weak | Oncternal Therapeutics, Inc. | Salim Yazji Chief Medical Officer | $7,200 25,000 shares | +18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.